{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:51:42Z","timestamp":1792662702681,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000738","name":"University of Leicester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ygyno.2019.11.020","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T08:56:23Z","timestamp":1574412983000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer"],"prefix":"10.1016","volume":"156","author":[{"given":"Anna","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2650-0172","authenticated-orcid":false,"given":"Esther","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_6","key":"10.1016\/j.ygyno.2019.11.020_bb0005","doi-asserted-by":"crossref","first-page":"vi33","DOI":"10.1093\/annonc\/mdt353","article-title":"Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Colombo","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0010","author":"CancerResearchUK"},{"issue":"7","key":"10.1016\/j.ygyno.2019.11.020_bb0015","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","article-title":"Classification of endometrial carcinoma: more than two types","volume":"15","author":"Murali","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9484","key":"10.1016\/j.ygyno.2019.11.020_bb0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"issue":"7447","key":"10.1016\/j.ygyno.2019.11.020_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.11.020_bb0030","article-title":"Adjuvant chemotherapy for endometrial cancer after hysterectomy","volume":"10","author":"Johnson","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0035","unstructured":"de Boer, S.M., et al., Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet Oncology."},{"issue":"11","key":"10.1016\/j.ygyno.2019.11.020_bb0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"22","author":"Fleming","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.020_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0050","series-title":"A Gynecologic Oncology Group Study","first-page":"125","article-title":"Randomized phase III noninferiority trial of first line chemotherapy for metastatic and recurrent endometrial carcinoma","author":"Miller","year":"2012"},{"issue":"10","key":"10.1016\/j.ygyno.2019.11.020_bb0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1634\/theoncologist.2010-0087","article-title":"Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents","volume":"15","author":"Moxley","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.020_bb0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2013.09.021","article-title":"Applicability of the concept of \u201cplatinum sensitivity\u201d to recurrent endometrial cancer: the SGSG-012\/GOTIC-004\/Intergroup study","volume":"131","author":"Nagao","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"31","key":"10.1016\/j.ygyno.2019.11.020_bb0065","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1200\/JCO.2015.61.7225","article-title":"Second-line therapy for endometrial cancer: the need for better options","volume":"33","author":"Fleming","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.11.020_bb0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00000421-200212000-00004","article-title":"Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"25","author":"Asbury","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.11.020_bb0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0090","first-page":"106","article-title":"Effects of progestational agents in treatment of endometrial carcinoma","volume":"66","author":"Podratz","year":"1985","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0095","article-title":"Hormonal therapy in advanced or recurrent endometrial cancer","volume":"12","author":"Kokka","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2019.11.020_bb0100","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2016.34.15_suppl.5520","article-title":"Phase II study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial\u2014ANZGOG 0903","volume":"34","author":"Mileshkin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial \u2013 ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40661-017-0056-7","article-title":"New therapies for advanced, recurrent, and metastatic endometrial cancers","volume":"4","author":"Makker","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"issue":"8","key":"10.1016\/j.ygyno.2019.11.020_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082348","article-title":"Modeling endometrial cancer: past, present, and future","volume":"19","author":"Van Nyen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yexcr.2012.09.012","article-title":"Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer","volume":"319","author":"Chitcholtan","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-10-38","article-title":"The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer","volume":"10","author":"Chitcholtan","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ncb3516","article-title":"Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium","volume":"19","author":"Turco","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.11.020_bb0135","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","article-title":"Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening","volume":"21","author":"Boretto","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.11.020_bb0140","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/IGC.0000000000001061","article-title":"The use of endometrial cancer patient\u2013derived organoid culture for drug sensitivity testing is feasible","volume":"27","author":"Girda","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2019.11.020_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cas.12898","article-title":"Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer","volume":"107","author":"Kiyohara","year":"2016","journal-title":"Cancer Sci."},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2019.11.020_bb0150","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ygyno.2019.11.020_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/toxsci\/62.2.299","article-title":"Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium","volume":"62","author":"Bofinger","year":"2001","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2018.03.031","article-title":"Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma","volume":"425","author":"Koikawa","year":"2018","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.ygyno.2019.11.020_bb0165","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.humpath.2008.02.008","article-title":"Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma","volume":"39","author":"Adegboyega","year":"2008","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd3870","article-title":"The role of tumour\u2013stromal interactions in modifying drug response: challenges and opportunities","volume":"12","author":"McMillin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14584","article-title":"A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle","volume":"8","author":"Xiao","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0180","series-title":"Metabolic Signaling: Methods and Protocols","first-page":"217","article-title":"Development of patient-derived tumor xenograft models","author":"Annibali","year":"2019"},{"issue":"8","key":"10.1016\/j.ygyno.2019.11.020_bb0185","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3390\/ijms19082431","article-title":"Patient-derived xenograft models for endometrial cancer research","volume":"19","author":"Moiola","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.020_bb0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10585-011-9444-2","article-title":"Generation and characterization of orthotopic murine models for endometrial cancer","volume":"29","author":"Cabrera","year":"2012","journal-title":"Clinical & Experimental Metastasis"},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2015.07.104","article-title":"Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies","volume":"139","author":"Depreeuw","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0200","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.ygyno.2019.11.020_bb0205","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/0008-5472.CAN-16-1121","article-title":"Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy","volume":"77","author":"Karekla","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0210","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/ncomms7169","article-title":"Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity","volume":"6","author":"Majumder","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.020_bb0215","first-page":"1029","article-title":"Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution","volume":"33","author":"Jung","year":"2013","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2019.11.020_bb0220","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ccr.2012.02.017","article-title":"Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance","volume":"21","author":"Nakasone","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ygyno.2019.11.020_bb0225","first-page":"255","article-title":"Critical evaluation of human endometrial explants as an ex vivo model system: a molecular approach","volume":"17","author":"Sch\u00e4fer","year":"2011","journal-title":"MHR: Basic science of reproductive medicine"},{"issue":"2","key":"10.1016\/j.ygyno.2019.11.020_bb0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1472-6483(10)61759-2","article-title":"Development and characterization of an endometrial tissue culture system","volume":"7","author":"Stavreus-Evers","year":"2003","journal-title":"Reprod. BioMed. Online"},{"key":"10.1016\/j.ygyno.2019.11.020_bb0235","article-title":"Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery","author":"Powley","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0015-0282(98)00400-2","article-title":"Whole explants of peritoneum and endometrium: a novel model of the early endometriosis lesion","volume":"71","author":"Witz","year":"1999","journal-title":"Fertil. Steril."},{"issue":"5","key":"10.1016\/j.ygyno.2019.11.020_bb0245","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0015-0282(03)02164-2","article-title":"Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis","volume":"80","author":"Fasciani","year":"2003","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0250","first-page":"49","article-title":"Expression of glycodelin and cyclooxygenase-2 in human endometrial tissue following three-dimensional culture","volume":"57","author":"Esfandiari","year":"2007"},{"issue":"Pt 3","key":"10.1016\/j.ygyno.2019.11.020_bb0255","first-page":"1027","article-title":"The expression of interstitial collagenase in human endometrium is controlled by progesterone and by oestradiol and is related to menstruation","volume":"305","author":"Marbaix","year":"1995"},{"key":"10.1016\/j.ygyno.2019.11.020_bb0260","first-page":"5848","article-title":"Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo","volume":"90","author":"Vassilev","year":"2005"},{"issue":"3","key":"10.1016\/j.ygyno.2019.11.020_bb0265","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cbi.2003.06.002","article-title":"Biotransformation of tamoxifen in a human endometrial explant culture model","volume":"146","author":"Sharma","year":"2003","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(03)01134-3","article-title":"Antioxidant inhibits tamoxifen\u2013DNA adducts in endometrial explant culture","volume":"307","author":"Sharma","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0275","first-page":"889","article-title":"Formation of Tamoxifen\u2212DNA adducts in human endometrial explants exposed to \u03b1-hydroxytamoxifen","volume":"18","author":"Yeon Kim","year":"2005"},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0280","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2008.09.002","article-title":"Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium","volume":"112","author":"Punyadeera","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.11.020_bb0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/toxsci\/62.2.289","article-title":"Expression of AhR and ARNT mRNA in cultured human endometrial explants exposed to TCDD","volume":"62","author":"Pitt","year":"2001","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2019.11.020_bb0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/ajpath.2010.090403","article-title":"Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1","volume":"176","author":"Sales","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2019.11.020_bb0295","doi-asserted-by":"crossref","unstructured":". Sales, K., et al., F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Vol. 148. 007. 3635\u201344.","DOI":"10.1210\/en.2006-1517"},{"issue":"31","key":"10.1016\/j.ygyno.2019.11.020_bb0300","doi-asserted-by":"crossref","first-page":"22118","DOI":"10.1074\/jbc.M601350200","article-title":"Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants","volume":"281","author":"Dolcet","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5, Supplement","key":"10.1016\/j.ygyno.2019.11.020_bb0305","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.fertnstert.2008.02.090","article-title":"Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix","volume":"91","author":"Khazaei","year":"2009","journal-title":"Fertil. Steril."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:56Z","timestamp":1758772016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0090825819316713"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}